Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Omega-3-Acid Ethyl Esters Softgel capsules, a generic version of Lovaza. The US market for the generic Lovaza is approximately $300 million per annum, as per IMS, with five generic players including Par Pharmaceutical (Par), an Endo International Company.
The company has partnered with Par to market the product in the United States. The product to be manufactured in its flagship facility in Bangalore will be launched immediately.
Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and semi-solids.
